ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
ANI Pharmaceuticals, Inc. (ANIP)
Last ani pharmaceuticals, inc. earnings: 2/27 08:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
anipharmaceuticals.com/investors_corporate_profile.php
Company Research
Source: Yahoo! Finance
Cortrophin Gel Revenue: $52.6 million, up 77% over Q3 2023. Generics Revenue: $78.2 million, an increase of 11% over Q3 2023. Gross Margin: 60%, a decrease of 3.9 points from the prior year period. Full Year 2024 Revenue Guidance: Raised to $594 million to $602 million. Full Year 2024 Cortrophin Gel Revenue Guidance: Raised to $196 million to $200 million. Full Year 2024 Adjusted Non-GAAP EBITDA Guidance: Raised to $149 million to $153 million. Full Year 2024 Adjusted Non-GAAP EPS Guidance: Raised to $4.90 to $5.05. Warning! GuruFocus has detected 4 Warning Signs with ANIP. Release Date: November 08, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript ANI Pharmaceuticals Inc ( NASDAQ:ANIP ) reported a 13% increase in total revenues for Q3 2024, reaching $148.3 million, driven by strong demand for Cortrophin Gel and generics. The acquisition of Amera is expected to be transformative for the rare disease busines
Show less
Read more
Impact Snapshot
Event Time:
ANIP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIP alerts
High impacting ANI Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ANIP
News
- Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? [Yahoo! Finance]Yahoo! Finance
- Gastroparesis Drugs Market size to increase by USD 1.42 Billion between 2023 to 2028, Market Segmentation by Drug Class, Disease Type, Geography, Technavio [Yahoo! Finance]Yahoo! Finance
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $80.00 price target on the stock.MarketBeat
- Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock? [Yahoo! Finance]Yahoo! Finance
ANIP
Earnings
- 11/8/24 - Beat
ANIP
Sec Filings
- 12/18/24 - Form 4
- 12/17/24 - Form 144
- 12/16/24 - Form 4
- ANIP's page on the SEC website